BRIEF published on 01/13/2025 at 11:31, 1 year 6 months ago Heights Capital Management dépasse 5% du capital de GenSight Biologics Augmentation De Capital GenSight Biologics Actions Et Droits De Vote Heights Capital Management Participation Capital
BRIEF published on 01/13/2025 at 11:31, 1 year 6 months ago Heights Capital Management exceeds 5% stake in GenSight Biologics Capital Increase Shares And Voting Rights GenSight Biologics Heights Capital Management Capital Participation
PRESS RELEASE published on 01/13/2025 at 11:26, 1 year 6 months ago Franchissement de seuils Déclaration de franchissement de seuils par Heights Capital Management, Inc. pour Gensight Biologics S.A. avec détention de 7 574 746 actions et 9,62% des droits de vote Déclaration Actions Franchissement De Seuils Gensight Biologics S.A. Heights Capital Management Inc.
BRIEF published on 12/24/2024 at 20:51, 1 year 7 months ago GenSight Biologics Secures €1.5 Million Financing from Existing Investors Investors Warrants Financing Gene Therapy GenSight Biologics
BRIEF published on 12/24/2024 at 20:51, 1 year 7 months ago GenSight Biologics obtient un financement de 1,5 million d'euros auprès d'investisseurs existants Financement Investisseurs Thérapie Génique Mandats GenSight Biologics
PRESS RELEASE published on 12/24/2024 at 20:46, 1 year 7 months ago Inside Information / Other news releases GenSight Biologics announces a c. €1.5 million financing from existing investors through a Reserved Offering to support gene therapy development for retinal diseases and CNS disorders Financing Gene Therapy GenSight Biologics Retinal Diseases Reserved Offering
PRESS RELEASE published on 12/24/2024 at 20:46, 1 year 7 months ago Informations privilégiées / Autres communiqués GenSight Biologics annonce un financement de 1,5 million d'euros auprès d'investisseurs existants pour le développement de thérapies géniques innovantes. Perspectives de croissance et objectifs à court terme Croissance Financement Investisseurs GenSight Biologics Thérapies Géniques
BRIEF published on 11/13/2024 at 07:35, 1 year 8 months ago GenSight Biologics Submits LUMEVOQ® Dossier to ANSM Gene Therapy GenSight Biologics Early Access Program Leber Hereditary Optic Neuropathy Regulatory Submission
BRIEF published on 11/13/2024 at 07:35, 1 year 8 months ago GenSight Biologics dépose le dossier LUMEVOQ® auprès de l'ANSM Thérapie Génique GenSight Biologics Programme D'accès Anticipé Neuropathie Optique Héréditaire De Leber Soumission Réglementaire
PRESS RELEASE published on 11/13/2024 at 07:30, 1 year 8 months ago Inside Information / Other news releases GenSight Biologics submits updated LUMEVOQ Dossier to ANSM for early access program restart in France to treat LHON, aiming for first injections in December 2024 GenSight Biologics LHON LUMEVOQ Early Access Program ANSM
Published on 08/07/2026 at 23:15, 1 day 4 hours ago Faraday Copper Reports Second Quarter 2026 Financial Results
Published on 08/07/2026 at 23:00, 1 day 4 hours ago Rio Grande Resources Announces up to $2,500,000 Non-Brokered Private Placement Financing
Published on 08/07/2026 at 22:30, 1 day 4 hours ago UraniumX Deploys $3.8 Million to Athabasca Basin Exploration
Published on 08/07/2026 at 22:15, 1 day 5 hours ago Noram Lithium Engages 1353656 BC Ltd. for Marketing and Management Consulting Services
Published on 08/09/2026 at 00:01, 3 hours 14 minutes ago Club Offers for Travel Enthusiasts in Germany
Published on 08/08/2026 at 16:25, 10 hours 49 minutes ago Bybit Sues North Korea and Lazarus Group, Secures Preliminary Injunction Freezing Stolen Assets in Landmark Crypto Asset Recovery Effort
Published on 08/07/2026 at 23:21, 1 day 3 hours ago EQS-Adhoc: Northern Data Group reports Q2 2026 including the adverse fair value movement on contingent consideration
Published on 08/07/2026 at 19:30, 1 day 7 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 08/07/2026 at 19:15, 1 day 8 hours ago ABO Energy Agrees Sale of Its Polish and Hungarian Subsidiaries
Published on 08/07/2026 at 18:54, 1 day 8 hours ago Covivio - Déclaration des transactions sur actions propres réalisées du 03 août 2026 au 07 août 2026
Published on 08/07/2026 at 18:54, 1 day 8 hours ago Covivio - Information on Treasury shares transactions between August 3rd, 2026, and August 7th, 2026
Published on 08/07/2026 at 18:40, 1 day 8 hours ago Disclosure of transactions in own shares from August 3 to August 7, 2026
Published on 08/07/2026 at 18:40, 1 day 8 hours ago Déclaration hebdomadaire d'opérations effectuées du 3 au 7 août 2026
Published on 08/07/2026 at 18:00, 1 day 9 hours ago LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 juillet 2026
